Published in Nat Rev Endocrinol on February 21, 2012
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE) | NCT00461630
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One (2013) 1.11
The glycine deportation system and its pharmacological consequences. Pharmacol Ther (2012) 0.85
Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol (2015) 0.83
Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. Am J Med (2016) 0.79
Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib. Vasc Health Risk Manag (2012) 0.78
Niacin promotes revascularization and recovery of limb function in diet-induced obese mice with peripheral ischemia. Pharmacol Res Perspect (2016) 0.75
Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place? Med Sci Monit (2015) 0.75
Sildenafil Therapy Normalizes the Aberrant Metabolomic Profile in the Comt(-/-) Mouse Model of Preeclampsia/Fetal Growth Restriction. Sci Rep (2015) 0.75
Leucine-nicotinic acid synergy stimulates AMPK/Sirt1 signaling and regulates lipid metabolism and lifespan in Caenorhabditis elegans, and hyperlipidemia and atherosclerosis in mice. Am J Cardiovasc Dis (2017) 0.75
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 15.39
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med (1990) 6.43
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 5.82
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther (2005) 5.41
Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation (2001) 4.82
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys (1955) 3.63
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med (2005) 3.45
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev (2006) 3.26
Haemostatic function and cardiovascular death: early results of a prospective study. Lancet (1980) 3.25
Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA (1994) 3.11
Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med (1993) 3.02
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med (2003) 2.97
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand (1988) 2.86
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA (1990) 2.78
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol (2005) 2.61
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med (2005) 2.40
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA (1990) 2.36
Safety considerations with niacin therapy. Am J Cardiol (2006) 2.30
Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun (2003) 2.00
High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation (2009) 2.00
High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol (2004) 2.00
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol (2008) 1.97
Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med (1989) 1.90
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol (2005) 1.73
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol (2009) 1.66
Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA (1990) 1.65
Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther (2007) 1.64
Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol (2010) 1.55
Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol (2008) 1.55
Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc (1991) 1.54
High density lipoprotein metabolism in man. J Clin Invest (1977) 1.53
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb (1994) 1.52
Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ (1990) 1.50
The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract (1992) 1.50
Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man. Metabolism (1961) 1.47
Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis (2008) 1.45
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A (2006) 1.44
Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men. J Cardiovasc Risk (1997) 1.40
Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol (2006) 1.39
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis (2009) 1.36
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res (2004) 1.31
HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol (2010) 1.29
Extended-release niacin raises adiponectin and leptin. Atherosclerosis (2006) 1.27
Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol (1997) 1.25
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol (2008) 1.25
Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol (2006) 1.19
Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol (2004) 1.16
Tolerance to nicotinic acid flushing. Clin Pharmacol Ther (1991) 1.15
Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol (2000) 1.13
High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism (1982) 1.10
Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc (2008) 1.08
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol (2007) 1.07
Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun (2004) 1.07
The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract (2007) 1.07
Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract (2005) 1.06
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol (2010) 1.06
Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest (1979) 1.06
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia (2007) 1.05
New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med (2004) 1.04
Nicotinic acid: an old drug with a promising future. Br J Pharmacol (2007) 1.04
Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther (1982) 1.03
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol (2003) 1.00
Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther (2009) 0.99
Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther (2007) 0.99
Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res (2008) 0.98
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf (2005) 0.98
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol (2009) 0.98
Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol (1999) 0.97
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol (2004) 0.95
Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol (2007) 0.94
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism (1998) 0.93
Antiatherothrombotic effects of nicotinic acid. Atherosclerosis (2003) 0.92
Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol (2009) 0.92
HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clin Biochem (1997) 0.90
Low-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin Administration. Am J Ther (1995) 0.90
Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital. West J Med (1991) 0.90
Hepatotoxicity associated with sustained-release niacin. Am J Med (1992) 0.88
Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med (1997) 0.88
Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am Heart J (2009) 0.87
Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx. Br J Pharmacol (2010) 0.84
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Hypertriglyceridemia: its etiology, effects and treatment. CMAJ (2007) 3.42
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Narrative review: statin-related myopathy. Ann Intern Med (2009) 2.36
N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med (2014) 2.28
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet (2010) 2.14
SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol (2002) 2.12
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest (2009) 1.83
Alstrom syndrome (OMIM 203800): a case report and literature review. Orphanet J Rare Dis (2007) 1.79
Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc Genet (2011) 1.78
Polygenic determinants of severe hypertriglyceridemia. Hum Mol Genet (2008) 1.77
Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov (2008) 1.74
Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis (2007) 1.72
The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med (2011) 1.70
TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. Am J Hum Genet (2011) 1.65
Genetic determinants of plasma triglycerides. J Lipid Res (2010) 1.63
Congenital and acquired long QT syndromes. Can J Cardiol (2003) 1.59
Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. Can J Cardiol (2008) 1.59
Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med (2006) 1.55
APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med (2008) 1.52
Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism. J Lipid Res (2007) 1.52
Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency. Nephrol Dial Transplant (2007) 1.49
Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients. Can J Cardiol (2012) 1.47
Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol (2007) 1.46
Complications of Type 2 Diabetes Among Aboriginal Canadians: prevalence and associated risk factors. Diabetes Care (2005) 1.46
Complex trait locus linkage mapping in atherosclerosis: time to take a step back before moving forward? Arterioscler Thromb Vasc Biol (2005) 1.46
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids Health Dis (2008) 1.41
LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J Hum Genet (2003) 1.40
Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. Can J Cardiol (2013) 1.39
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes (2009) 1.36
The heritability of mammographically dense and nondense breast tissue. Cancer Epidemiol Biomarkers Prev (2006) 1.35
Extremes of unexplained variation as a phenotype: an efficient approach for genome-wide association studies of cardiovascular disease. Circ Cardiovasc Genet (2010) 1.33
Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet (2009) 1.30
Advances in genomic analysis of stroke: what have we learned and where are we headed? Stroke (2010) 1.30
Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ (2006) 1.30
Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol (2009) 1.30
Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Hum Genet (2003) 1.29
Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation (2009) 1.26
Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke (2004) 1.26
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25
Exome sequencing as a diagnostic tool for pediatric-onset ataxia. Hum Mutat (2014) 1.25
Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovasc Diabetol (2008) 1.23
DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet (2002) 1.22
Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis (2008) 1.20
Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem (2005) 1.19
Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. CMAJ (2009) 1.19
Meta-analysis of the INSIG2 association with obesity including 74,345 individuals: does heterogeneity of estimates relate to study design? PLoS Genet (2009) 1.18
Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. Mol Genet Metab (2007) 1.16
Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J Biol Chem (2006) 1.15
Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can J Physiol Pharmacol (2009) 1.15
Genetic determinants of statin intolerance. Lipids Health Dis (2007) 1.15
Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care (2008) 1.14
Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. J Lipid Res (2009) 1.14
HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis (2007) 1.14
Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis (2005) 1.13
Noninvasive phenotypes of atherosclerosis: similar windows but different views. Stroke (2004) 1.13
Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol (2011) 1.12
Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia. J Biol Chem (2007) 1.12
Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease. Genome Med (2009) 1.12
Temtamy preaxial brachydactyly syndrome is caused by loss-of-function mutations in chondroitin synthase 1, a potential target of BMP signaling. Am J Hum Genet (2010) 1.11
Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis (2006) 1.11
Phenomics: expanding the role of clinical evaluation in genomic studies. J Investig Med (2010) 1.10
Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol (2011) 1.10
Low incidence of cardiovascular disease among the Inuit--what is the evidence? Atherosclerosis (2003) 1.09
Association of parity with risk of type 2 diabetes and related metabolic disorders. Diabetes Care (2002) 1.08
A multiplex human syndrome implicates a key role for intestinal cell kinase in development of central nervous, skeletal, and endocrine systems. Am J Hum Genet (2009) 1.08
Validation of automatically classified magnetic resonance images for carotid plaque compositional analysis. Stroke (2005) 1.08
Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis (2013) 1.08
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J Clin Invest (2010) 1.06
Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J Lipid Res (2004) 1.06
Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol (2012) 1.06
HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. Proc Natl Acad Sci U S A (2002) 1.06
A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. J Biol Chem (2003) 1.05
Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability. Am J Hum Genet (2013) 1.03
Functional linkage between the endoplasmic reticulum protein Hsp47 and procollagen expression in human vascular smooth muscle cells. J Biol Chem (2002) 1.03
Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I. J Lipid Res (2009) 1.03
Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids Health Dis (2005) 1.03
Evaluation of adipose tissue volume quantification with IDEAL fat-water separation. J Magn Reson Imaging (2011) 1.03
A comparison of ultrasound measurements to assess carotid atherosclerosis development in subjects with and without type 2 diabetes. Cardiovasc Ultrasound (2005) 1.02
APOA1 related amyloidosis: a case report and literature review. Clin Biochem (2003) 1.02
Copy number variation in the human genome and its implications for cardiovascular disease. Circulation (2007) 1.02
Optimizing RNA extraction yield from whole blood for microarray gene expression analysis. Clin Biochem (2004) 1.02
Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol (2013) 1.01
Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications (2007) 1.00